Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems01:22

Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems

Bioavailability is a critical pharmacological concept that measures the extent and rate at which an active drug ingredient or therapeutic moiety enters the systemic circulation, remaining unchanged. It's a pivotal factor in determining a drug's efficacy and safety.The Biopharmaceutics Classification System (BCS) plays an essential role in drug development by categorizing drugs into four classes based on their solubility and permeability. This classification aids in understanding drug absorption...
Biopharmaceutics and Pharmacokinetics: Overview01:28

Biopharmaceutics and Pharmacokinetics: Overview

Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the appropriate...
Plant Breeding and Biotechnology01:59

Plant Breeding and Biotechnology

Crop cultivation has a long history in human civilization, with records showing the cultivation of cereal plants beginning at around 8000 BC. This early plant breeding was developed primarily to provide a steady supply of food.
Biopharmaceutical Factors Influencing Drug Product Design: Overview01:22

Biopharmaceutical Factors Influencing Drug Product Design: Overview

Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though pharmacologically...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Donor-Targeted Anti-HLA-A2 Antibody Shows Nanogram-Level Efficacy in a Novel GVHD Mouse Model.

bioRxiv : the preprint server for biology·2025
Same author

Generation of time-synchronized two-color X-ray free-electron laser pulses using phase shifters.

Scientific reports·2023
Same author

Morphological changes in the superficial medial collateral ligament on knee MR imaging: association with medial meniscal extrusion and posterior root medial meniscus abnormality.

Skeletal radiology·2021
Same author

Time-resolved resonant elastic soft x-ray scattering at Pohang Accelerator Laboratory X-ray Free Electron Laser.

The Review of scientific instruments·2020
Same author

Association of meniscal flounce in the knee with the pattern and location of meniscal tear, concomitant ligamentous injury, amount of knee joint effusion, and flexion and rotation angles: a magnetic resonance evaluation.

Skeletal radiology·2020
Same author

Stripline beam position monitor for X-ray free electron laser of Pohang Accelerator Laboratory.

The Review of scientific instruments·2019

Related Experiment Video

Updated: Jun 11, 2026

A Protocol for Using Gene Set Enrichment Analysis to Identify the Appropriate Animal Model for Translational Research
09:35

A Protocol for Using Gene Set Enrichment Analysis to Identify the Appropriate Animal Model for Translational Research

Published on: August 16, 2017

Revisiting risk-adjusted Net Present Value: a practical framework for biotechnology valuation.

Ju Han Yeon1, Chunkyu Kim2, Heung-Sik Kang1

  • 1Department of Technology Practical Convergence, Chungnam National University, 99, Daehak-ro, Yuseong-gu, Daejeon, the Republic of Korea.

Drug Discovery Today
|June 9, 2026
PubMed
Summary
This summary is machine-generated.

A new modified risk-adjusted Net Present Value (mrNPV) method offers superior biotechnology valuation by incorporating R&D costs, success probability, and failure costs. This approach provides a more accurate financial assessment for early-stage drug development compared to traditional methods.

Keywords:
R&D managementbiotechnology valuationinvestment valuemrMPVrNPV

More Related Videos

Quantification, Viability Assessment, and Visualization Strategies for Acinetobacter Biofilms
07:41

Quantification, Viability Assessment, and Visualization Strategies for Acinetobacter Biofilms

Published on: August 4, 2023

Related Experiment Videos

Last Updated: Jun 11, 2026

A Protocol for Using Gene Set Enrichment Analysis to Identify the Appropriate Animal Model for Translational Research
09:35

A Protocol for Using Gene Set Enrichment Analysis to Identify the Appropriate Animal Model for Translational Research

Published on: August 16, 2017

Quantification, Viability Assessment, and Visualization Strategies for Acinetobacter Biofilms
07:41

Quantification, Viability Assessment, and Visualization Strategies for Acinetobacter Biofilms

Published on: August 4, 2023

Area of Science:

  • Biotechnology
  • Pharmaceutical Valuation
  • Financial Modeling

Background:

  • Traditional risk-adjusted valuation methods inadequately assess early-stage biotechnology due to high failure rates, long development timelines, and significant R&D costs.
  • Existing models fail to fully incorporate the complexities of drug development, leading to inaccurate financial projections.

Purpose of the Study:

  • To introduce a revised valuation methodology, the modified risk-adjusted Net Present Value (mrNPV), designed to overcome limitations in assessing early-stage biotechnology.
  • To provide a more accurate financial framework for valuing pharmaceutical assets under development.

Main Methods:

  • Developed the modified risk-adjusted Net Present Value (mrNPV) methodology.
  • Incorporated key factors: R&D expenses, probability of success, projected sales, risk timing, and cost of failure.
  • Applied the mrNPV method to value a diabetic drug in development.

Main Results:

  • The mrNPV method valued a diabetic drug at over US$3 billion, with free cash flow exceeding US$300 million.
  • Demonstrated a significant increase in valuation compared to traditional methods.
  • Validated the practical applicability of the mrNPV approach in biotechnology valuation.

Conclusions:

  • The mrNPV methodology offers a more robust and accurate approach to valuing early-stage biotechnology assets.
  • This revised method bridges the gap between theoretical valuation frameworks and the practical financial needs of the industry.
  • The mrNPV method is essential for precise financial assessment in the dynamic biotech sector.